Log in

CVE:MDP - Pediapharm Stock Price, Forecast & News

+0.20 (+5.26 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
Now: C$4.00
50-Day Range
MA: C$3.66
52-Week Range
Now: C$4.00
Volume22,600 shs
Average Volume8,054 shs
Market CapitalizationC$56.23 million
P/E RatioN/A
Dividend YieldN/A
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It distributes prescription medicines that are used to treat pathological conditions, which primarily affect children from infancy to 18 years of age; and commercializes non-prescription products, such as non-prescription drugs and medical devices that fulfill unmet medical needs of children. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was incorporated in 2003 and is headquartered in Verdun, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesC$61.47 million
Cash FlowC$1.75 per share
Book ValueC$2.13 per share



Market CapC$56.23 million
Next Earnings Date7/13/2020 (Estimated)

Receive MDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter.

Pediapharm (CVE:MDP) Frequently Asked Questions

What is Pediapharm's stock symbol?

Pediapharm trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MDP."

When is Pediapharm's next earnings date?

Pediapharm is scheduled to release their next quarterly earnings announcement on Monday, July 13th 2020. View Earnings Estimates for Pediapharm.

What price target have analysts set for MDP?

2 Wall Street analysts have issued 12 month price targets for Pediapharm's shares. Their forecasts range from C$6.50 to C$6.50. On average, they expect Pediapharm's share price to reach C$6.50 in the next twelve months. This suggests a possible upside of 62.5% from the stock's current price. View Analyst Price Targets for Pediapharm.

What is the consensus analysts' recommendation for Pediapharm?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pediapharm in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pediapharm.

Has Pediapharm been receiving favorable news coverage?

News headlines about MDP stock have trended very negative recently, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pediapharm earned a news sentiment score of -4.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Pediapharm.

Who are some of Pediapharm's key competitors?

What other stocks do shareholders of Pediapharm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pediapharm investors own include Enghouse Systems (ENGH), Ag Growth International (AFN), Gatekeeper Systems (GSI) and Antibe Therapeutics (ATE).

Who are Pediapharm's key executives?

Pediapharm's management team includes the folowing people:
  • Mr. Sylvain Chretien, Pres & Director (Age 55)
  • Mr. Roland Boivin, Chief Financial Officer
  • Mr. Richard Labelle, VP of Sales & Marketing
  • Mr. Benoît Hébert, VP of Bus. Devel. & Licensing (Age 51)
  • Mr. Normand Chartrand, Consultant (Age 60)

How do I buy shares of Pediapharm?

Shares of MDP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Pediapharm's stock price today?

One share of MDP stock can currently be purchased for approximately C$4.00.

How big of a company is Pediapharm?

Pediapharm has a market capitalization of C$56.23 million and generates C$61.47 million in revenue each year. View Additional Information About Pediapharm.

What is Pediapharm's official website?

The official website for Pediapharm is http://www.medexus.com/.

How can I contact Pediapharm?

The company can be reached via phone at 514-762-2626.

MarketBeat Community Rating for Pediapharm (CVE MDP)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  15 (Vote Outperform)
Underperform Votes:  9 (Vote Underperform)
Total Votes:  24
MarketBeat's community ratings are surveys of what our community members think about Pediapharm and other stocks. Vote "Outperform" if you believe MDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Featured Article: What is Green Investing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel